Every 8-K that COMPASS Pathways Plc (CMPS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CMPS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CMPS filings page.
Compass Pathways plc reported results for the three and six months ended June 30, 2026 and outlined clinical, regulatory and launch progress for COMP360 psilocybin in treatment-resistant depression (TRD) and PTSD. Two positive Phase 3 TRD trials showed rapid onset and durable benefit through at least 6 months, with 39% of participants in COMP006 and 25% in COMP005 achieving a ≥25% reduction in MADRS at Week 6 and maintaining benefit on average to Week 26. A rolling New Drug Application submission for COMP360 in TRD is underway, with final modules expected in the fourth quarter of 2026 and potential U.S. commercial launch targeted for the first half of 2027, subject to FDA approval and DEA and state rescheduling.
Research and development expenses were $29.2 million in Q2 2026, slightly below Q2 2025, while general and administrative expenses rose to $23.2 million, driven by commercial preparedness. Net loss for Q2 2026 widened to $253.8 million (loss of $1.88 per share), primarily due to a $205.6 million non-cash loss from fair value changes in warrant liabilities. Cash and cash equivalents were $433.3 million and debt $50.7 million as of June 30, 2026, and the company expects its cash to fund operations into 2028.
Compass Pathways reports new 26-week Phase 3 COMP006 data for its COMP360 psilocybin treatment in treatment-resistant depression and outlines an accelerated U.S. approval path. In nearly 600 participants, 39% of those receiving 25 mg achieved a clinically meaningful ≥25% reduction in MADRS scores by Week 6 and on average maintained benefit through at least Week 26, with additional dosing moving some into remission.
Serious adverse events were low and similar between arms over 26 weeks, at 6.3% in the 1 mg arm and 5.7% in the 25 mg arm, and most adverse events were transient on the day of dosing. A rolling NDA submission with the FDA is underway, with final submission expected in Q4 2026 and a potential U.S. launch in the first half of 2027, subject to FDA approval and DEA rescheduling.
Compass Pathways plc reported the results of its 2026 Annual General Meeting held on May 27, 2026. Shareholders representing 58,880,058 ordinary shares were present in person or by proxy. The company did not exercise discretionary voting power over American Depositary Shares lacking voting instructions, which were counted as broker non-votes.
Shareholders re-elected Justin Gover, Daphne Karydas and Jeffrey Jonas as directors and elected Kathleen Tregoning to the board. They also re-appointed PwC UK as U.K. statutory auditors, ratified PwC US as independent registered public accounting firm for 2026 and authorized the Audit and Risk Committee to determine auditors’ remuneration.
Investors approved the receipt of the U.K. statutory annual accounts for the year ended December 31, 2025 and noted that no dividend is recommended for that year. They also approved, on a non-binding, advisory basis, the directors’ remuneration report and the compensation of named executive officers. Following the meeting, Annalisa Jenkins’ eight-year term on the board concluded.
Compass Pathways reported a strong start to 2026, combining major regulatory progress for its COMP360 psilocybin treatment in treatment-resistant depression with a sharp improvement in reported results. The FDA granted a rolling New Drug Application submission and review, which is already underway, and a Commissioner’s National Priority Voucher that may shorten review timelines.
Part B 26-week data from the COMP006 Phase 3 trial are expected in early Q3 2026, with final NDA submission still targeted for Q4 and launch readiness by year-end. Cash and cash equivalents rose to $466.0 million as of March 31, 2026, supporting a runway into 2028. For the quarter, research and development expenses were $26.5 million and general and administrative expenses were $16.4 million, while a non-cash $130.9 million warrant fair value gain drove net income of $91.2 million versus a prior-year net loss.
Compass Pathways reported a much larger full-year 2025 net loss of $287.9 million (vs. $155.1 million in 2024), driven mainly by a $122.6 million non-cash fair value loss on warrant liabilities. Operating expenses were broadly flat, with R&D at $118.4 million and G&A at $60.6 million.
Cash and cash equivalents were $149.6 million at December 31, 2025, with debt of $31.6 million at that date (and $50.4 million by March 24, 2026). After a $150 million financing and $200 million warrant exercises, the company expects its cash position as of March 24, 2026 to fund operations into 2028.
Clinically, COMP360 achieved positive Phase 3 results in treatment‑resistant depression across large trials, showing rapid and durable responses with a generally well-tolerated safety profile. Compass plans a rolling NDA submission with completion expected in Q4 2026, aims to be launch-ready by the end of 2026, and is initiating a Phase 2b/3 PTSD trial following FDA IND acceptance.
Compass Pathways plc is raising new equity capital through an underwritten public offering of 17,500,000 American Depositary Shares (ADSs) at $8.00 per ADS and pre-funded warrants to purchase up to 1,250,000 ADSs at $7.999 per warrant. Underwriters also have a 30‑day option to buy up to 2,812,500 additional ADSs. Gross proceeds are expected to be $150.0 million before fees and expenses. All securities are being sold by the company, with closing expected around February 20, 2026, subject to customary conditions.
The pre-funded warrants carry a nominal exercise price of $0.0001 per ADS, are exercisable immediately, and include a Beneficial Ownership Limitation generally capped at 9.99%, which holders can adjust up to 19.99% with notice. The company, its officers and directors have agreed to a 60‑day lock-up on additional sales.
Compass Pathways intends to use net proceeds, together with existing cash, to fund its COMP005 and COMP006 Phase 3 trials, its Phase 2b/3 COMP360 PTSD program, accelerate commercial readiness activities, and for working capital and general corporate purposes.
Compass Pathways reported strongly positive topline results from both pivotal Phase 3 trials of its COMP360 psilocybin treatment for treatment‑resistant depression. In COMP005, a single 25 mg dose showed a highly statistically significant mean MADRS improvement versus placebo of -3.6 points at Week 6 (p<0.001), with rapid onset from the day after dosing and durability out to Week 26 for many responders. In COMP006, two 25 mg doses given three weeks apart achieved a -3.8‑point difference versus 1 mg at Week 6 (p<0.001), with 39% of patients reaching a clinically meaningful ≥25% MADRS reduction. Across more than 800 treated patients in these Phase 3 arms, COMP360 was generally well-tolerated; most adverse events such as headache, nausea, anxiety and visual hallucinations occurred on dosing days and resolved within a day, and serious suicidal events were rare and mainly in lower‑dose or control arms. The company plans to meet the FDA to discuss rolling NDA submission and expects to complete an NDA for COMP360 in Q4, supported by Breakthrough Therapy designation.
Compass Pathways entered a third amendment to its loan and security agreement with Hercules Capital, creating an amended term loan facility of up to $150 million across five tranches. The first tranche of $50 million is funded at closing, with a portion used to repay about $31.1 million of principal and PIK interest under the prior agreement. Additional tranches of up to $30 million each are tied to clinical and FDA approval milestones, plus a $20 million commercial milestone tranche and a further $20 million subject to Hercules’ investment committee.
The loans bear interest at the greater of 9.75% or 2.75% plus the Wall Street Journal prime rate, with interest-only payments until the first principal payment in the first quarter of 2029 and a scheduled maturity on January 5, 2031. The amendment includes facility and end-of-term charges, prepayment premiums, and is secured by substantially all personal property assets, along with minimum cash and performance covenants and customary default provisions.
COMPASS Pathways plc furnished an update on November 4, 2025, announcing it issued a press release with financial results for the nine months ended September 30, 2025. The release is included as Exhibit 99.1 and the information under Item 2.02 is furnished, not filed, under the Exchange Act.
American Depositary Shares trade on the Nasdaq Global Select Market under CMPS. The report was signed by Chief Financial Officer Teri Loxam.
COMPASS Pathways (CMPS) appointed Jeff Jonas, M.D. to its Board as a Class II director, effective October 29, 2025. He will serve on the audit and risk committee and the scientific committee. Upon joining, he will receive an option to purchase 52,000 ordinary shares (or an equivalent number of ADSs) with an exercise price set at the ADS closing price on the grant date, vesting in 36 equal monthly installments over three years.
Dr. Jonas brings leadership experience from Cure Ventures, Sage Therapeutics, ABio‑X, and multiple biotech boards. He will be eligible for annual cash retainers of $40,000 for Board service, $10,000 for audit and risk committee membership, and $6,000 for scientific committee membership. As part of a planned transition, Thomas Lönngren will retire from the Board effective December 31, 2025, and his decision was not due to any disagreement with the company.
Compass Pathways plc (CMPS) filed an 8-K to disclose that its pivotal Phase 3 COMP005 study met its primary endpoint in treatment-resistant depression (TRD). In the randomized, double-blind trial (n = 258 across 32 U.S. sites), a single 25 mg dose of COMP360 psilocybin produced a statistically significant reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) scores versus placebo at week 6 (mean difference −3.6 points; 95% CI [−5.7, −1.5]; p < 0.001). Safety, reviewed by the independent DSMB on 19 June 2025, was consistent with prior studies and showed no new or unexpected adverse signals, including suicidality.
COMP005 has three parts, with Parts A (through week 6) now unblinded, Part B blinded to week 26, and Part C open-label through week 52. The parallel COMP006 trial (planned n = 568) compares two fixed dosing regimens and remains blinded. The company expects to release 26-week data for COMP005 after all COMP006 participants complete Part A; 26-week COMP006 data are targeted for H2 2026.
The positive read-out strengthens CMPS’s regulatory pathway, but the FDA has not yet reviewed the data, full safety assessments are pending, and additional capital will likely be required to complete development and pursue commercialization. Forward-looking statements highlight clinical, regulatory, and financing risks.